| scholarly article | Q13442814 |
| P50 | author | Stephen J. Russell | Q53843820 |
| Ronald S Go | Q56990716 | ||
| Morie A Gertz | Q57052163 | ||
| Jonas Paludo | Q61066815 | ||
| S. Vincent Rajkumar | Q61123608 | ||
| David Dingli | Q66385573 | ||
| Martha Q Lacy | Q66419394 | ||
| Shaji K Kumar | Q85960198 | ||
| Sikander Ailawadhi | Q87584539 | ||
| Paul G. Richardson | Q87712102 | ||
| Wilson I Gonsalves | Q88037405 | ||
| Francis K Buadi | Q88774336 | ||
| Prashant Kapoor | Q89921551 | ||
| Vivek Roy | Q90151377 | ||
| Taimur Sher | Q90151380 | ||
| Joseph Mikhael | Q92398872 | ||
| Craig B Reeder | Q94562059 | ||
| Suzanne R Hayman | Q96475488 | ||
| John A. Lust | Q110810892 | ||
| Asher A Chanan Khan | Q114300389 | ||
| P Leif Bergsagel | Q114300391 | ||
| Betsy R LaPlant | Q114300411 | ||
| Alese E Halvorson | Q114300412 | ||
| Angela Dispenzieri | Q37838558 | ||
| P2093 | author name string | Nelson Leung | |
| Rafael Fonseca | |||
| A Keith Stewart | |||
| Yi Lin | |||
| P2860 | cites work | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | Q57904272 |
| Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma | Q24605861 | ||
| Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Q24614147 | ||
| Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma | Q24647620 | ||
| Multiple myeloma | Q24655964 | ||
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma | Q33389111 | ||
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial | Q33410172 | ||
| A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma | Q33412684 | ||
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival | Q33412804 | ||
| Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | Q33431778 | ||
| Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma | Q33434817 | ||
| Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | Q33435789 | ||
| Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease | Q35794132 | ||
| Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma | Q35935794 | ||
| Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Q36274834 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study | Q37655019 | ||
| Bone marrow microenvironment in multiple myeloma progression. | Q38055141 | ||
| Targeting the bone marrow microenvironment in multiple myeloma. | Q38289041 | ||
| In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. | Q38968027 | ||
| Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. | Q39485433 | ||
| Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. | Q42921022 | ||
| Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. | Q43088298 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dexamethasone | Q422252 |
| P577 | publication date | 2017-07-06 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma |
| Q26741620 | Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trials |
| Q92771675 | EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies |
| Q91844274 | Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone |
| Q90241569 | Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma |
| Q92662638 | Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools |
| Q64901832 | Navigating the treatment landscape in multiple myeloma: which combinations to use and when? |
| Q55064105 | Panobinostat and Multiple Myeloma in 2018. |
| Q92056747 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial |
| Q47562624 | Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma |
| Q89819339 | Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma |
| Q92088331 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial |
| Q47339695 | The proteasome and proteasome inhibitors in multiple myeloma |
| Q39177792 | Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy |
| Q47770089 | Triplet vs. doublet drug regimens for managing multiple myeloma. |
Search more.